- Home
- EQ vs CMBM Comparison
EQ vs CMBM Comparison
Compare EQ & CMBM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQ
- CMBM
- Stock Information
- Founded
- EQ 2017
- CMBM 2011
- Country
- EQ United States
- CMBM United States
- Employees
- EQ N/A
- CMBM N/A
- Industry
- EQ Biotechnology: Pharmaceutical Preparations
- CMBM Radio And Television Broadcasting And Communications Equipment
- Sector
- EQ Health Care
- CMBM Technology
- Exchange
- EQ Nasdaq
- CMBM Nasdaq
- Market Cap
- EQ 12.2M
- CMBM 14.3M
- IPO Year
- EQ 2018
- CMBM 2019
- Fundamental
- Price
- EQ $0.41
- CMBM $1.11
- Analyst Decision
- EQ Buy
- CMBM Strong Buy
- Analyst Count
- EQ 3
- CMBM 2
- Target Price
- EQ $3.00
- CMBM $5.50
- AVG Volume (30 Days)
- EQ 519.6K
- CMBM 1.6M
- Earning Date
- EQ 08-07-2025
- CMBM 08-07-2025
- Dividend Yield
- EQ N/A
- CMBM N/A
- EPS Growth
- EQ N/A
- CMBM N/A
- EPS
- EQ N/A
- CMBM N/A
- Revenue
- EQ $30,406,000.00
- CMBM $172,215,000.00
- Revenue This Year
- EQ N/A
- CMBM N/A
- Revenue Next Year
- EQ N/A
- CMBM $17.73
- P/E Ratio
- EQ N/A
- CMBM N/A
- Revenue Growth
- EQ N/A
- CMBM N/A
- 52 Week Low
- EQ $0.27
- CMBM $0.23
- 52 Week High
- EQ $1.50
- CMBM $2.19
- Technical
- Relative Strength Index (RSI)
- EQ 60.48
- CMBM 72.21
- Support Level
- EQ $0.29
- CMBM $0.65
- Resistance Level
- EQ $0.43
- CMBM $1.49
- Average True Range (ATR)
- EQ 0.06
- CMBM 0.16
- MACD
- EQ 0.01
- CMBM 0.08
- Stochastic Oscillator
- EQ 64.21
- CMBM 65.52
About EQ Equillium Inc.
Equillium Inc is a clinical-stage biotechnology company engaged in developing novel therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company intends to commercialize its product candidates either independently or through partnerships, or otherwise monetize its pipeline through strategic transactions. Itolizumab (EQ001), a clinical-stage product candidate, is an anti-CD6 immune-modifying monoclonal antibody, or mAb, that selectively targets the CD6-ALCAM signaling pathway to downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. The company's other clinical-stage and pre-clinical-stage candidates include EQ101 and EQ302.
About CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.